Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

This article was originally published in PharmAsia News

Executive Summary

Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18

You may also be interested in...



AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach

AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach

Takeda Shifts Resources In U.S. For "Promotionally Sensitive" Brands

TOKYO - Takeda Pharmaceutical Feb. 3 reported a 53.7 percent net earnings jump for the April-December 2009 period from the same period a year ago as it was released from the drag of its Millennium Pharmaceutical acquisition costs, but - as has affected all Japanese pharma - sales of its core projects were generally soft because of the yen's rise against the U.S. dollar

Related Content

UsernamePublicRestriction

Register

SC071699

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel